Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma

Keklik, Muzaffer; Karakus, Esen; Kaynar, Leylagül; Akyol, Gulsah; Güven, Zeynep Tuğba; Çelik, Serhat; Baydar, Mustafa; Şanli, Neslihan Mandaci; Ünal, Ali; Çetın, Mustafa

doi:10.1016/j.transci.2020.102844

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard therapy in transplant-eligible patients with MM [36]. Furthermore, HSC mobilization and collection have been performed via chemotherapy administration, hematopoietic growth factors administration (including G-CSF or GM-CSF), or chemotherapy plus hematopoietic growth factor [37][38][39][40]. Plerixafor, a small-molecule bicyclam, reversibly binds to CXCR4 and antagonizes SDF-1α interaction.…”

Section: Roles Of Sdf-1α/cxcr4 On Mobilization In MMmentioning

confidence: 99%

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma

Ito

Sato

Maeta

2021

Cancers

View full text Add to dashboard Cite

The C-X-C chemokine receptor type 4 (CXCR4) is a pleiotropic chemokine receptor that is expressed in not only normal hematopoietic cells but also multiple myeloma cells. Its ligand, stromal cell-derived factor 1α (SDF-1α) is produced in the bone marrow microenvironment. The SDF-1α/CXCR4 axis plays a pivotal role in the major physiological processes associated with tumor proliferation, survival, invasion, dissemination, and drug resistance in myeloma cells. This review summarizes the pleiotropic role of the SDF-1α/CXCR4 axis in multiple myeloma and discusses the future perspective in the SDF-1α/CXCR4 axis-targeted therapies in multiple myeloma.

show abstract

Section: Roles Of Sdf-1α/cxcr4 On Mobilization In MMmentioning

confidence: 99%

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma

Ito

Sato

Maeta

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Additionally, previous studies have shown that cyclophosphamide does not only significantly enhance the immunoreactivity of organisms, especially tumor-bearing CD8 + T-cells, to tumor antigens but also promotes the generation and release of CD34 + cells from the bone marrow. The CD34 + cells enhance the effect of granulocyte colony-stimulating factor (G-CSF) [71,72].…”

mentioning

confidence: 99%

Insight into the Prospects for Tumor Therapy Based on Photodynamic Immunotherapy

et al. 2022

View full text Add to dashboard Cite

Malignancy is one of the common diseases with high mortality worldwide and the most important obstacle to improving the overall life expectancy of the population in the 21st century. Currently, single or combined treatments, including surgery, chemotherapy, and radiotherapy, are still the mainstream regimens for tumor treatment, but they all present significant side effects on normal tissues and organs, such as organ hypofunction, energy metabolism disorders, and various concurrent diseases. Based on this, theranostic measures for the highly selective killing of tumor cells have always been a hot area in cancer-related fields, among which photodynamic therapy (PDT) is expected to be an ideal candidate for practical clinical application due to its precise targeting and excellent safety performance, so-called PDT refers to a therapeutic method mainly composed of photosensitizers (PSs), laser light, and reactive oxygen species (ROS). Photoimmunotherapy (PIT), a combination of PDT and immunotherapy, can induce systemic antitumor immune responses and inhibit continuing growth and distant metastasis of residual tumor cells, demonstrating a promising application prospect. This article reviews the types of immune responses that occur in the host after PDT treatment, including innate and adaptive immunity. To further help PIT-related drugs improve their pharmacokinetic properties and bioavailability, we highlight the potential improvement of photodynamic immunotherapy from three aspects: immunostimulatory agents, tumor-associated antigens (TAAs) as well as different immune cells. Finally, we focus on recent advances in various strategies and shed light on their corresponding mechanisms of immune activation and possible clinical applications such as cancer vaccines. Having discovered the inherent potential of PDT and the mechanisms that PDT triggers host immune responses, a variety of immunotherapeutic strategies have been investigated in parallel with approaches to improve PDT efficiency. However, it remains to be further elucidated under what conditions the immune effect induced by PDT can achieve tumor immunosuppression and to what extent PDT-induced antitumor immunity will lead to complete tumor rejection. Currently, PIT presents several outstanding intractable challenges, such as the aggregation ability of PSs locally in tumors, deep tissue penetration ability of laser light, immune escape, and biological toxicity, and it is hoped that these issues raised will help to point out the direction of preclinical research on PIT and accelerate its transition to clinical practice.

show abstract

Retrospective comparison of two different cell separators for autologous peripheral blood stem cell collection: Single center experience

Keklik

2024

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma

Cited by 3 publications

References 15 publications

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma

Insight into the Prospects for Tumor Therapy Based on Photodynamic Immunotherapy

Retrospective comparison of two different cell separators for autologous peripheral blood stem cell collection: Single center experience

Contact Info

Product

Resources

About